| scholarly article | Q13442814 |
| P2093 | author name string | Marra CM | |
| Tyler KL | |||
| Simpson DM | |||
| Singer EJ | |||
| Clifford DB | |||
| McArthur JC | |||
| Francis GS | |||
| Hyslop NE | |||
| Glicksman M | |||
| Piliero PJ | |||
| Tselis AC | |||
| Yiannoutsos C | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P304 | page(s) | 623-625 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy | |
| P478 | volume | 52 |
| Q90234526 | A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy |
| Q34548429 | AIDS and AIDS-treatment neuropathies |
| Q77776707 | AIDS and AIDS-treatment neuropathies |
| Q30351230 | AIDS-associated progressive multifocal leukoencephalopathy : current management strategies. |
| Q35112030 | Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. |
| Q34466555 | Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality |
| Q45723886 | Analysis of JC virus genotype distribution and transcriptional control region rearrangements in human immunodeficiency virus-positive progressive multifocal leukoencephalopathy patients with and without highly active antiretroviral treatment |
| Q24599841 | CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes |
| Q38025878 | CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflamm |
| Q80161248 | Case 15: when a stroke is not a stroke |
| Q34675035 | Central nervous system infections in individuals with HIV-1 infection |
| Q35112681 | Challenges for Clinical Trials to Treat Progressive Multifocal Leukoencephalopathy |
| Q34343677 | Challenges for clinical trials on progressive multifocal leukoencephalopathy |
| Q45400146 | Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis |
| Q43716024 | Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring |
| Q46802879 | Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy |
| Q30250271 | Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls |
| Q30787775 | Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). |
| Q42251011 | Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. |
| Q34343681 | Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. |
| Q37180600 | Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function |
| Q44527255 | Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. |
| Q80008415 | Evolution of neuro-AIDS during the HAART era |
| Q45730279 | Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution |
| Q36143108 | Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. |
| Q73238537 | Focal Brain Lesions in People with HIV |
| Q32042586 | Focal neurological disease in patients with acquired immunodeficiency syndrome |
| Q35355938 | From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients |
| Q34051589 | Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole |
| Q80086394 | Guidelines for the diagnosis and management of neurological complications of HIV infection |
| Q34719884 | High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy |
| Q42701998 | Human Polyomavirus-Associated Cerebral Disorders in the Post-HAART Era |
| Q36771908 | Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. |
| Q39877627 | Identification and characterization of mefloquine efficacy against JC virus in vitro |
| Q33279746 | Identification of DDX1 as a JC virus transcriptional control region-binding protein |
| Q43649915 | Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy |
| Q37028699 | Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy |
| Q37678580 | Immune surveillance and response to JC virus infection and PML. |
| Q28478894 | Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy |
| Q44170598 | Improvement in onychomycosis after initiation of combined antiretroviral therapy |
| Q35459188 | Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). |
| Q30787765 | Inflammatory Reaction in Progressive Multifocal Leukoencephalopathy: Harmful or Beneficial? |
| Q34647087 | Inhibition of large T antigen ATPase activity as a potential strategy to develop anti-polyomavirus JC drugs |
| Q41727049 | Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle-based assays |
| Q26852060 | JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? |
| Q37183930 | JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy |
| Q35899152 | JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. |
| Q74412115 | JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy |
| Q58322056 | Leucoencefalopatía multifocal progresiva: desde el origen a 2008 |
| Q48114351 | Longitudinal study of two cases of progressive multifocal leukoencephalopathy with a clinical benign evolution |
| Q35609239 | Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. |
| Q36233526 | Management of infections by the human polyomavirus JC: past, present and future |
| Q30327314 | Maximizing life's potentials in AIDS: a psychopharmacologic update. |
| Q37002062 | Myelin basic protein-specific T lymphocytes proliferation and programmed cell death in demyelinating diseases. |
| Q36622383 | Natalizumab and progressive multifocal leucoencephalopathy |
| Q37290643 | Natalizumab for the treatment of relapsing multiple sclerosis |
| Q34409340 | Natalizumab in the treatment of multiple sclerosis |
| Q28243804 | Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring |
| Q36518544 | Neuroepidemiology and the epidemiology of viral infections of the nervous system |
| Q33590337 | Neurologic presentations of AIDS. |
| Q36450742 | Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study |
| Q37977963 | Neurological complications in HIV. |
| Q41067770 | Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study |
| Q34378701 | Neurological manifestations of HIV-1 infection in the HAART era. |
| Q82029838 | Neuropharmacology of HIV/AIDS |
| Q30352753 | New trends in progressive multifocal leukoencephalopathy |
| Q30824043 | Opportunistic infections of the CNS in patients with AIDS: diagnosis and management |
| Q42279234 | PML therapy: "It's Déjà vu all over again". |
| Q33398308 | PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids |
| Q28731034 | Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease |
| Q74256276 | Progressive Multifocal Leukoencephalopathy |
| Q37156649 | Progressive multifocal leucoencephalopathy in HIV/AIDS: observational study from a tertiary care centre in northern India |
| Q36533129 | Progressive multifocal leukoence--phalopathy presenting as homonymous hemianopia in a patient with acquired immunodeficiency syndrome |
| Q81521025 | Progressive multifocal leukoencephalopathy |
| Q82029803 | Progressive multifocal leukoencephalopathy |
| Q38577593 | Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). |
| Q37885823 | Progressive multifocal leukoencephalopathy and natalizumab |
| Q33763351 | Progressive multifocal leukoencephalopathy and other forms of JC virus disease |
| Q33506561 | Progressive multifocal leukoencephalopathy in HIV-1 infection |
| Q37663449 | Progressive multifocal leukoencephalopathy in a 62-year-old immunocompetent woman |
| Q37755922 | Progressive multifocal leukoencephalopathy: what's new? |
| Q34122368 | Prophylaxis of opportunistic infections. |
| Q34529503 | Pur-Alpha Induces JCV Gene Expression and Viral Replication by Suppressing SRSF1 in Glial Cells |
| Q40570699 | Rehabilitation outcome of progressive multifocal leukoencephalopathy in HIV-positive patients: a report of two cases |
| Q28704590 | T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors |
| Q30787783 | The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology |
| Q30797688 | The changing pattern of HIV neuropathology in the HAART era. |
| Q43716016 | The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. |
| Q58794493 | The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS |
| Q37141010 | The role of polyomaviruses in human disease |
| Q37180338 | Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066) |
| Q33348210 | Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy |
| Q34087794 | Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside |
| Q48251245 | Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience |
| Q54708693 | [Progressive multifocal leukoencephalopathy confirmed by PCR for JC virus in cerebrospinal fluid: case report]. |
| Q82421983 | [Role of immunity in the development of progressive multifocal leukoencephalopathy: a report of three patients with type B lymphoma and humoral immunodeficiency and six others with acquired immunodeficiency syndrome] |
Search more.